GSM3020220 |
ATAC-seq on PBMCs from donor ND-1, CD4Tcell |
GSM3020221 |
ATAC-seq on PBMCs from donor ND-2, CD4Tcell |
GSM3020222 |
ATAC-seq on PBMCs from donor ND-3, CD4Tcell |
GSM3020223 |
ATAC-seq on PBMCs from donor ND-1, CD8Tcell |
GSM3020224 |
ATAC-seq on PBMCs from donor ND-2, CD8Tcell |
GSM3020225 |
ATAC-seq on PBMCs from donor ND-3, CD8Tcell |
GSM3020226 |
ATAC-seq on PBMCs from donor ND-1, NaiveBcell |
GSM3020227 |
ATAC-seq on PBMCs from donor ND-2, NaiveBcell |
GSM3020228 |
ATAC-seq on PBMCs from donor ND-3, NaiveBcell |
GSM3020229 |
ATAC-seq on PBMCs from donor ND-1, SwitchedBcell |
GSM3020230 |
ATAC-seq on PBMCs from donor ND-2, SwitchedBcell |
GSM3020231 |
ATAC-seq on PBMCs from donor ND-3, SwitchedBcell |
GSM3020232 |
ATAC-seq on PBMCs from donor ND-1, Tcell |
GSM3020233 |
ATAC-seq on PBMCs from donor ND-2, Tcell |
GSM3020234 |
ATAC-seq on PBMCs from donor ND-3, Tcell |
GSM3020235 |
ATAC-seq on PBMCs from donor ND-1, UnswitchedBcell |
GSM3020236 |
ATAC-seq on PBMCs from donor ND-2, UnswitchedBcell |
GSM3020237 |
ATAC-seq on PBMCs from donor ND-3, UnswitchedBcell |
GSM3020238 |
ATAC-seq on PBMCs from patient CLL1 on day 0 of ibrutinib treatment, Bcell cells |
GSM3020239 |
ATAC-seq on PBMCs from patient CLL1 on day 3 of ibrutinib treatment, Bcell cells |
GSM3020240 |
ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, Bcell cells |
GSM3020241 |
ATAC-seq on PBMCs from patient CLL1 on day 0 of ibrutinib treatment, CD4 cells |
GSM3020242 |
ATAC-seq on PBMCs from patient CLL1 on day 3 of ibrutinib treatment, CD4 cells |
GSM3020243 |
ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, CD4 cells, replicate 1 |
GSM3020244 |
ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, CD4 cells, replicate 2 |
GSM3020245 |
ATAC-seq on PBMCs from patient CLL1 on day 0 of ibrutinib treatment, CD8 cells |
GSM3020246 |
ATAC-seq on PBMCs from patient CLL1 on day 3 of ibrutinib treatment, CD8 cells |
GSM3020247 |
ATAC-seq on PBMCs from patient CLL1 on day 030 of ibrutinib treatment, CD8 cells |
GSM3020248 |
ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, CD8 cells |
GSM3020249 |
ATAC-seq on PBMCs from patient CLL1 on day 0 of ibrutinib treatment, CLL cells |
GSM3020250 |
ATAC-seq on PBMCs from patient CLL1 on day 3 of ibrutinib treatment, CLL cells |
GSM3020251 |
ATAC-seq on PBMCs from patient CLL1 on day 030 of ibrutinib treatment, CLL cells |
GSM3020252 |
ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, CLL cells |
GSM3020253 |
ATAC-seq on PBMCs from patient CLL1 on day 0 of ibrutinib treatment, NK cells |
GSM3020254 |
ATAC-seq on PBMCs from patient CLL1 on day 3 of ibrutinib treatment, NK cells |
GSM3020255 |
ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, NK cells, replicate 1 |
GSM3020256 |
ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, NK cells, replicate 2 |
GSM3020257 |
ATAC-seq on PBMCs from patient CLL2 on day 0 of ibrutinib treatment, Bcell cells |
GSM3020258 |
ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, Bcell cells |
GSM3020259 |
ATAC-seq on PBMCs from patient CLL2 on day 30 of ibrutinib treatment, Bcell cells |
GSM3020260 |
ATAC-seq on PBMCs from patient CLL2 on day 120 of ibrutinib treatment, Bcell cells |
GSM3020261 |
ATAC-seq on PBMCs from patient CLL2 on day 0 of ibrutinib treatment, CD4 cells |
GSM3020262 |
ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, CD4 cells |
GSM3020263 |
ATAC-seq on PBMCs from patient CLL2 on day 8 of ibrutinib treatment, CD4 cells |
GSM3020264 |
ATAC-seq on PBMCs from patient CLL2 on day 30 of ibrutinib treatment, CD4 cells |
GSM3020265 |
ATAC-seq on PBMCs from patient CLL2 on day 120 of ibrutinib treatment, CD4 cells |
GSM3020266 |
ATAC-seq on PBMCs from patient CLL2 on day 0 of ibrutinib treatment, CD8 cells |
GSM3020267 |
ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, CD8 cells |
GSM3020268 |
ATAC-seq on PBMCs from patient CLL2 on day 8 of ibrutinib treatment, CD8 cells |
GSM3020269 |
ATAC-seq on PBMCs from patient CLL2 on day 30 of ibrutinib treatment, CD8 cells |
GSM3020270 |
ATAC-seq on PBMCs from patient CLL2 on day 120 of ibrutinib treatment, CD8 cells |
GSM3020271 |
ATAC-seq on PBMCs from patient CLL2 on day 0 of ibrutinib treatment, CLL cells |
GSM3020272 |
ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, CLL cells |
GSM3020273 |
ATAC-seq on PBMCs from patient CLL2 on day 8 of ibrutinib treatment, CLL cells |
GSM3020274 |
ATAC-seq on PBMCs from patient CLL2 on day 30 of ibrutinib treatment, CLL cells |
GSM3020275 |
ATAC-seq on PBMCs from patient CLL2 on day 120 of ibrutinib treatment, CLL cells |
GSM3020276 |
ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, Mono cells |
GSM3020277 |
ATAC-seq on PBMCs from patient CLL2 on day 120 of ibrutinib treatment, Mono cells |
GSM3020278 |
ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, NK cells |
GSM3020279 |
ATAC-seq on PBMCs from patient CLL2 on day 8 of ibrutinib treatment, NK cells |
GSM3020280 |
ATAC-seq on PBMCs from patient CLL2 on day 30 of ibrutinib treatment, NK cells |
GSM3020281 |
ATAC-seq on PBMCs from patient CLL2 on day 150 of ibrutinib treatment, NK cells |
GSM3020282 |
ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, Bcell cells |
GSM3020283 |
ATAC-seq on PBMCs from patient CLL4 on day 0 of ibrutinib treatment, CD4 cells |
GSM3020284 |
ATAC-seq on PBMCs from patient CLL4 on day 2 of ibrutinib treatment, CD4 cells |
GSM3020285 |
ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, CD4 cells |
GSM3020286 |
ATAC-seq on PBMCs from patient CLL4 on day 0 of ibrutinib treatment, CD8 cells |
GSM3020287 |
ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, CD8 cells |
GSM3020288 |
ATAC-seq on PBMCs from patient CLL4 on day 0 of ibrutinib treatment, CLL cells |
GSM3020289 |
ATAC-seq on PBMCs from patient CLL4 on day 2 of ibrutinib treatment, CLL cells |
GSM3020290 |
ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, CLL cells |
GSM3020291 |
ATAC-seq on PBMCs from patient CLL4 on day 0 of ibrutinib treatment, Mono cells |
GSM3020292 |
ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, Mono cells |
GSM3020293 |
ATAC-seq on PBMCs from patient CLL4 on day 0 of ibrutinib treatment, NK cells |
GSM3020294 |
ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, NK cells |
GSM3020295 |
ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, Bcells, replicate 1 |
GSM3020296 |
ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, Bcells, replicate 2 |
GSM3020297 |
ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, Bcell cells |
GSM3020298 |
ATAC-seq on PBMCs from patient CLL5 on day 2 of ibrutinib treatment, Bcell cells |
GSM3020299 |
ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, Bcell cells |
GSM3020300 |
ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, Bcell cells |
GSM3020301 |
ATAC-seq on PBMCs from patient CLL5 on day 30 of ibrutinib treatment, Bcell cells |
GSM3020302 |
ATAC-seq on PBMCs from patient CLL5 on day 150 of ibrutinib treatment, Bcell cells |
GSM3020303 |
ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, CD4 cells |
GSM3020304 |
ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, CD4 cells |
GSM3020305 |
ATAC-seq on PBMCs from patient CLL5 on day 2 of ibrutinib treatment, CD4 cells |
GSM3020306 |
ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, CD4 cells |
GSM3020307 |
ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, CD4 cells |
GSM3020308 |
ATAC-seq on PBMCs from patient CLL5 on day 30 of ibrutinib treatment, CD4 cells |
GSM3020309 |
ATAC-seq on PBMCs from patient CLL5 on day 150 of ibrutinib treatment, CD4 cells |
GSM3020310 |
ATAC-seq on PBMCs from patient CLL5 on day 240 of ibrutinib treatment, CD4 cells |
GSM3020311 |
ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, CD8 cells |
GSM3020312 |
ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, CD8 cells |
GSM3020313 |
ATAC-seq on PBMCs from patient CLL5 on day 2 of ibrutinib treatment, CD8 cells |
GSM3020314 |
ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, CD8 cells |
GSM3020315 |
ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, CD8 cells |
GSM3020316 |
ATAC-seq on PBMCs from patient CLL5 on day 30 of ibrutinib treatment, CD8 cells |
GSM3020317 |
ATAC-seq on PBMCs from patient CLL5 on day 150 of ibrutinib treatment, CD8 cells |
GSM3020318 |
ATAC-seq on PBMCs from patient CLL5 on day 240 of ibrutinib treatment, CD8 cells |
GSM3020319 |
ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, CLL cells |
GSM3020320 |
ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, CLL cells |
GSM3020321 |
ATAC-seq on PBMCs from patient CLL5 on day 2 of ibrutinib treatment, CLL cells |
GSM3020322 |
ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, CLL cells |
GSM3020323 |
ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, CLL cells |
GSM3020324 |
ATAC-seq on PBMCs from patient CLL5 on day 30 of ibrutinib treatment, CLL cells |
GSM3020325 |
ATAC-seq on PBMCs from patient CLL5 on day 150 of ibrutinib treatment, CLL cells |
GSM3020326 |
ATAC-seq on PBMCs from patient CLL5 on day 240 of ibrutinib treatment, CLL cells |
GSM3020327 |
ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, Mono cells |
GSM3020328 |
ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, Mono cells |
GSM3020329 |
ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, Mono cells |
GSM3020330 |
ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, Mono cells |
GSM3020331 |
ATAC-seq on PBMCs from patient CLL5 on day 150 of ibrutinib treatment, Mono cells |
GSM3020332 |
ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, NK cells |
GSM3020333 |
ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, NK cells |
GSM3020334 |
ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, NK cells |
GSM3020335 |
ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, NK cells |
GSM3020336 |
ATAC-seq on PBMCs from patient CLL5 on day 030 of ibrutinib treatment, NK cells |
GSM3020337 |
ATAC-seq on PBMCs from patient CLL5 on day 30 of ibrutinib treatment, NK cells |
GSM3020338 |
ATAC-seq on PBMCs from patient CLL6 on day 120 of ibrutinib treatment, Bcell cells |
GSM3020339 |
ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, Bcell cells |
GSM3020340 |
ATAC-seq on PBMCs from patient CLL6 on day 030 of ibrutinib treatment, CD4 cells |
GSM3020341 |
ATAC-seq on PBMCs from patient CLL6 on day 120 of ibrutinib treatment, CD4 cells |
GSM3020342 |
ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, CD4 cells |
GSM3020343 |
ATAC-seq on PBMCs from patient CLL6 on day 0 of ibrutinib treatment, CD8 cells |
GSM3020344 |
ATAC-seq on PBMCs from patient CLL6 on day 030 of ibrutinib treatment, CD8 cells |
GSM3020345 |
ATAC-seq on PBMCs from patient CLL6 on day 120 of ibrutinib treatment, CD8 cells |
GSM3020346 |
ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, CD8 cells |
GSM3020347 |
ATAC-seq on PBMCs from patient CLL6 on day 0 of ibrutinib treatment, CLL cells |
GSM3020348 |
ATAC-seq on PBMCs from patient CLL6 on day 030 of ibrutinib treatment, CLL cells |
GSM3020349 |
ATAC-seq on PBMCs from patient CLL6 on day 120 of ibrutinib treatment, CLL cells |
GSM3020350 |
ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, CLL cells |
GSM3020351 |
ATAC-seq on PBMCs from patient CLL6 on day 0 of ibrutinib treatment, Mono cells |
GSM3020352 |
ATAC-seq on PBMCs from patient CLL6 on day 030 of ibrutinib treatment, Mono cells |
GSM3020353 |
ATAC-seq on PBMCs from patient CLL6 on day 120 of ibrutinib treatment, Mono cells |
GSM3020354 |
ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, Mono cells |
GSM3020355 |
ATAC-seq on PBMCs from patient CLL6 on day 030 of ibrutinib treatment, NK cells |
GSM3020356 |
ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, NK cells |
GSM3020357 |
ATAC-seq on PBMCs from patient CLL7 on day 0 of ibrutinib treatment, Bcell cells |
GSM3020358 |
ATAC-seq on PBMCs from patient CLL7 on day 3 of ibrutinib treatment, Bcell cells |
GSM3020359 |
ATAC-seq on PBMCs from patient CLL7 on day 150 of ibrutinib treatment, Bcell cells |
GSM3020360 |
ATAC-seq on PBMCs from patient CLL7 on day 0 of ibrutinib treatment, CD4 cells |
GSM3020361 |
ATAC-seq on PBMCs from patient CLL7 on day 1 of ibrutinib treatment, CD4 cells |
GSM3020362 |
ATAC-seq on PBMCs from patient CLL7 on day 3 of ibrutinib treatment, CD4 cells |
GSM3020363 |
ATAC-seq on PBMCs from patient CLL7 on day 8 of ibrutinib treatment, CD4 cells |
GSM3020364 |
ATAC-seq on PBMCs from patient CLL7 on day 30 of ibrutinib treatment, CD4 cells |
GSM3020365 |
ATAC-seq on PBMCs from patient CLL7 on day 150 of ibrutinib treatment, CD4 cells |
GSM3020366 |
ATAC-seq on PBMCs from patient CLL7 on day 0 of ibrutinib treatment, CD8 cells |
GSM3020367 |
ATAC-seq on PBMCs from patient CLL7 on day 1 of ibrutinib treatment, CD8 cells |
GSM3020368 |
ATAC-seq on PBMCs from patient CLL7 on day 3 of ibrutinib treatment, CD8 cells |
GSM3020369 |
ATAC-seq on PBMCs from patient CLL7 on day 8 of ibrutinib treatment, CD8 cells |
GSM3020370 |
ATAC-seq on PBMCs from patient CLL7 on day 30 of ibrutinib treatment, CD8 cells |
GSM3020371 |
ATAC-seq on PBMCs from patient CLL7 on day 150 of ibrutinib treatment, CD8 cells |
GSM3020372 |
ATAC-seq on PBMCs from patient CLL7 on day 0 of ibrutinib treatment, CLL cells |
GSM3020373 |
ATAC-seq on PBMCs from patient CLL7 on day 1 of ibrutinib treatment, CLL cells |
GSM3020374 |
ATAC-seq on PBMCs from patient CLL7 on day 3 of ibrutinib treatment, CLL cells |
GSM3020375 |
ATAC-seq on PBMCs from patient CLL7 on day 8 of ibrutinib treatment, CLL cells |
GSM3020376 |
ATAC-seq on PBMCs from patient CLL7 on day 30 of ibrutinib treatment, CLL cells |
GSM3020377 |
ATAC-seq on PBMCs from patient CLL7 on day 150 of ibrutinib treatment, CLL cells |
GSM3020378 |
ATAC-seq on PBMCs from patient CLL7 on day 0 of ibrutinib treatment, NK cells |
GSM3020379 |
ATAC-seq on PBMCs from patient CLL7 on day 30 of ibrutinib treatment, NK cells |
GSM3020380 |
ATAC-seq on PBMCs from patient CLL7 on day 150 of ibrutinib treatment, NK cells |
GSM3020381 |
ATAC-seq on PBMCs from patient CLL8 on day 0 of ibrutinib treatment, CD4 cells |
GSM3020382 |
ATAC-seq on PBMCs from patient CLL8 on day 3 of ibrutinib treatment, CD4 cells |
GSM3020383 |
ATAC-seq on PBMCs from patient CLL8 on day 0 of ibrutinib treatment, CD8 cells |
GSM3020384 |
ATAC-seq on PBMCs from patient CLL8 on day 3 of ibrutinib treatment, CD8 cells |
GSM3020385 |
ATAC-seq on PBMCs from patient CLL8 on day 030 of ibrutinib treatment, CD8 cells |
GSM3020386 |
ATAC-seq on PBMCs from patient CLL8 on day 0 of ibrutinib treatment, CLL cells |
GSM3020387 |
ATAC-seq on PBMCs from patient CLL8 on day 3 of ibrutinib treatment, CLL cells |
GSM3020388 |
ATAC-seq on PBMCs from patient CLL8 on day 030 of ibrutinib treatment, CLL cells |
GSM3020389 |
ATAC-seq on PBMCs from patient CLL8 on day 0 of ibrutinib treatment, Mono cells |
GSM3020390 |
ATAC-seq on PBMCs from patient CLL8 on day 3 of ibrutinib treatment, Mono cells |
GSM3020391 |
ATAC-seq on PBMCs from patient CLL8 on day 0 of ibrutinib treatment, NK cells |
GSM3020392 |
ATAC-seq on PBMCs from patient CLL8 on day 3 of ibrutinib treatment, NK cells |
GSM3020393 |
scRNA-seq on PBMCs from patient CLL1 after 0 days of ibrutinib treatment |
GSM3020394 |
scRNA-seq on PBMCs from patient CLL1 after 120 days of ibrutinib treatment |
GSM3020395 |
scRNA-seq on PBMCs from patient CLL5 after 0 days of ibrutinib treatment |
GSM3020396 |
scRNA-seq on PBMCs from patient CLL5 after 150 days of ibrutinib treatment |
GSM3020397 |
scRNA-seq on PBMCs from patient CLL5 after 30 days of ibrutinib treatment |
GSM3020398 |
scRNA-seq on PBMCs from patient CLL6 after 0 days of ibrutinib treatment |
GSM3020399 |
scRNA-seq on PBMCs from patient CLL6 after 120 days of ibrutinib treatment |
GSM3020400 |
scRNA-seq on PBMCs from patient CLL6 after 280 days of ibrutinib treatment |
GSM3020401 |
scRNA-seq on PBMCs from patient CLL6 after 30 days of ibrutinib treatment |
GSM3020402 |
scRNA-seq on PBMCs from patient CLL8 after 0 days of ibrutinib treatment |
GSM3020403 |
scRNA-seq on PBMCs from patient CLL8 after 120 days of ibrutinib treatment |
GSM3020404 |
scRNA-seq on PBMCs from patient CLL8 after 30 days of ibrutinib treatment |